VolitionRx joins €6.3M French sepsis detection program
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq hits intraday record high on tech boost, Mideast negotiation hopes
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil prices rise on Trump timeline for Iran peace deal: after US elections
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
VolitionRx Shares Further Details and Video of the DETECSEPS Program Launch in France
September 17, 2026 9:17 AM EDTHENDERSON, Nev., Sept. 17, 2026 /PRNewswire/ --Â VolitionRx Limited (NYSE AMERICAN: VNRX) (XASE: VNRX) (together with affiliates "Volition"), a multi-national epigenetics company, as part of the Government-funded DETECSEPS Consortium in France, today shares further details about the official launch of the... More
